Anti emetic efficacy of Low dose Olanzapine non-Inferior to high dose in patients with Solid tumors
Olanzapine is an effective antiemetic medication, but it can cause significant drowsiness when taken at the standard dose.
According to a study published in The Lancet Oncology, olanzapine 2·5 mg demonstrates non-inferiority compared to 10·0 mg in antiemetic efficacy and a reduced incidence of daytime drowsiness among patients receiving highly emetic chemotherapy.
The study evaluated the effectiveness of giving patients with solid tumors a low dose of olanzapine compared to the standard dose after undergoing highly emetogenic chemotherapy.
This study was conducted at Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India. Patients aged 13–75 years with an Eastern Cooperative Oncology Group performance status of 0–2 who received doxorubicin–cyclophosphamide or high-dose cisplatin for a solid tumour were eligible.
Patients were randomly assigned to receive either low-dose (2.5 mg) or standard-dose (10.0 mg) oral olanzapine, with block randomization and stratification based on sex, age, and chemotherapy regimen. The study's primary endpoint was complete control, defined as no emetic episodes, no rescue medications, and no or mild nausea, assessed in the modified intention-to-treat population. Daytime somnolence was the safety endpoint of interest, and non-inferiority was shown if the upper limit of the one-sided 95% CI for the difference in the complete control proportions excluded the non-inferiority margin of 10.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.